Reyvow Tablet
Product Images NDC 0002-4312

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Reyvow (NDC 0002-4312). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Reyvow 100mg 8ct 042 01

Reyvow (lasmiditan) 100 mg oral tablets packaging label showing a box containing 8 tablets (2 cards of 4 tablets). The label indicates each tablet contains 100 mg of lasmiditan and includes dosage instructions to dispense an enclosed Medication Guide with each patient. Manufactured and marketed by Eli Lilly and Company with the Lilly logo prominently displayed.*

FDA Label Image

Reyvow 50mg 8ct 040 01

Reyvow 50 mg tablets packaging label for lasmiditan oral tablets. The label indicates each tablet contains 50 mg of lasmiditan, with a total of 8 tablets (two cards of 4 tablets each). It is marked Rx only and includes the Lilly logo and Eli Lilly and Company as the manufacturer. The label also states to dispense the enclosed Medication Guide to each patient.*

FDA Label Image

Figure 1 (Reyvow Uspi 1 V1)

A line graph depicting the percent of patients achieving migraine pain freedom over time in hours from dose for Reyvow tablets at 200 mg, 100 mg, 50 mg, and placebo. The x-axis shows time from 0 to 2 hours, and the y-axis displays percent achieving pain freedom from 0% to 100%. Four distinct lines represent the different dosages and placebo.*

FDA Label Image

Figure 2 (Reyvow Uspi 2 V1)

A line graph showing the percent of patients achieving MBS (Most Bothersome Symptom) freedom over time in hours from dose for Reyvow tablets at 50 mg, 100 mg, and 200 mg doses compared to placebo. The x-axis represents time in hours post-dose from 0 to 2 hours, and the y-axis represents percent achieving MBS freedom from 0% to 100%. Reyvow doses show a higher percent achieving MBS freedom compared to placebo, with all three doses trending upward over the 2-hour period.*

FDA Label Image

Structural Formula (Reyvow Uspi Chem V1)

Chemical structure of lasmiditan, the active ingredient in Reyvow oral tablets. The structure depicts a fluorinated aromatic ring, a piperidine moiety, and other functional groups characteristic of this molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.